Sign in with Google
Universal Vision Biotechnology (3218 TT): Steady Growth Continued in 1H23 Riding on Strong Demand
397 Views11 Oct 2023 17:27
SUMMARY
- Universal Vision Biotechnology (3218 TT) reported continued growth in 1H23, with revenue, operating profit, and net profit increasing 25%, 31%, and 31%, YoY, respectively.
- Revenue from high-margin technical service grew 23% YoY, driven by increasing number of refractive and cataract surgeries performed in Taiwan. UVB dominates refractive market in Taiwan, with 50% market share.
- With dominant market positioning in Taiwan, re-opening in China, secular market tailwinds, and widening geographic presence, UVB is expected to report double-digit top and bottom-line growth through 2025.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »- Gold Miners ETF (GDX US): BIG Impact of Benchmark Change
- Shin Kong (2888 TT)/Taishin (2887 TT) - Short Timer, FX Risk, Index Flows - Time To Buy Vs Peers
- Santos (STO AU): XRG Consortium's Big Offer; Index Impact
- MV Global Junior Gold Miners Index Rebalance: Stocks at Their Highs
- Pop Mart (9992 HK): Beyond Blind Boxes -Jewellery Debut. Stock Up 200% YTD. Is It Still a Buy?
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Universal Vision Biotechnology (3218 TT): There Are Plenty of Near-Term Pain Points14 Apr 2025
- Universal Vision Biotechnology (3218 TT): Steady Revenue and Net Profit Growth in 2022;31 Mar 2023
- Universal Vision Biotechnology (3218 TT): Not Suffering from Myopia; Clear Long-Term Growth Prospect05 Jan 2023
- Universal Vision Biotechnology (3218 TT): 2021 Revenue Growth of 28% Is Outlier Amid COVID-19 Crisis03 Feb 2022
x